Zampa Germano, Moscato Michele, Brannigan Brian W, Morabito Alessandro, Bell Daphne W, Normanno Nicola
Oncology Unit, San Paolo Hospital, Civitavecchia, Italy.
Lung Cancer. 2008 Jun;60(3):452-4. doi: 10.1016/j.lungcan.2007.11.002. Epub 2008 Feb 20.
We describe two non-small-cell lung cancer (NSCLC) patients in which treatment with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs) gefitinib produced a prolonged control of bone disease. In the first patient, a 48-year-old male with adenocarcinoma (ADC) of the lung and multiple bone metastases, the bone scan became completely negative following treatment with gefitinib for 9 months. The patient remained alive and with no evidence of bone metastases for 20 months, despite two local recurrences that were surgically removed. Similarly, the bone scan of the second patient, a 49-year-old male with ADC of the lung and bone metastases, became negative after 6 months on gefitinib. The molecular mechanisms potentially involved in this phenomenon are discussed.
我们描述了两名非小细胞肺癌（NSCLC）患者，表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）吉非替尼治疗对其骨病产生了长期控制效果。在首例患者中，一名48岁男性，患有肺腺癌（ADC）并伴有多处骨转移，使用吉非替尼治疗9个月后骨扫描结果完全转为阴性。尽管有两次局部复发并接受了手术切除，但该患者存活了20个月，期间无骨转移迹象。同样，第二例患者为一名49岁男性，患有肺ADC并伴有骨转移，使用吉非替尼6个月后骨扫描转为阴性。本文还讨论了这一现象可能涉及的分子机制。
